

RNA Technologies

For further volumes:
<http://www.springer.com/series/8619>

Volker A. Erdmann • Jan Barciszewski
Editors

From Nucleic Acids Sequences to Molecular Medicine

 Springer

Editors

Prof. Dr. Volker A. Erdmann
Free University Berlin
Institute of Chemistry/Biochemistry
Thielallee 63
14195 Berlin
Germany
vae@zedat.fu-berlin.de

Prof. Dr. Jan Barciszewski
Polish Academy of Sciences
Institute of Bioorganic Chemistry
Z. Noskowskiego 12/14
61-704 Poznan
Poland
jan.barciszewski@ibch.poznan.pl

ISBN 978-3-642-27425-1

ISBN 978-3-642-27426-8 (eBook)

DOI 10.1007/978-3-642-27426-8

Springer Heidelberg New York Dordrecht London

Library of Congress Control Number: 2012940711

© Springer-Verlag Berlin Heidelberg 2012

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

Preface

Nucleic Acids Meet Human Genetic Medicine

With this volume of the series RNA Technologies, we aim to cover current and important developments in RNA chemistry, RNA biology, and the application of RNA molecules in molecular medicine.

Cellular gene expression is based on several levels of information. First the sequence of the canonical adenine, cytosine, guanosine, and thymine bases in DNA encodes for the primary structures of proteins through their specific base triplet arrangements. The “Central Dogma of Molecular Biology” taught us that the DNA is transcribed into RNAs and the protein-coding messenger RNA genes are then translated into proteins by ribosomes. For its function the ribosomes are directly dependent upon noncoding RNAs such as ribosomal RNAs, tRNAs, and small nuclear RNA. It is now evident that RNA, in gene expression, functions far beyond the established roles of these RNAs, for example, in RNA splicing and editing, telomere maintenance, protein secretion, small-molecule sensing, and reaction catalysis. Thus, RNA molecules play a key role in several fundamental cellular processes, serving as a carrier of genetic information and, very importantly, also as its regulator.

In human eukaryotic cells only ca. 1.8% of the genomic DNA is transcribed into mRNAs, while the remaining 98.2% represents the so-called noncoding DNA sequences. As discovered over the last 20 years, a large amount of this noncoding DNA represents actually noncoding RNA. The important role of noncoding RNAs in cellular processes has recently become more and more apparent. How RNA achieves its large number of different functions with a limited assortment of four different building blocks is still a question of great interest, and the answer lies in deciphering the RNA structures at its different levels of complexity. More detailed knowledge about the structural and functional properties of ribonucleic acids, and how they are functioning in the cells, is still required before methods can be developed to use these regulators in solving the problems in molecular medicine. In this book, up-to-date studies are presented, which follow exactly this goal: to

understand the structures and functions of RNA molecules and to use this information for applications in cellular biology and molecular medicine.

Over 25 years ago, the central dogma of molecular biology was expanded with the discovery that in addition to proteins, ribonucleic acids can also exhibit enzymatic activities. These RNA enzymes (ribozymes) spurred intense studies into the structural basis of RNA catalysis. All naturally occurring ribozymes catalyze phosphodiester transfer or hydrolysis with exquisite substrate specificity.

Thus, RNA has received increasing interest as a target of chemotherapy and as chemotherapeutic agents to be applied in molecular medicine. The demonstration that synthetic oligonucleotides could be used to interfere with biological information transfer in the 1970s of the last century induced a great interest to a novel type of therapy. Oligomeric nucleic acid-based therapeutics can be subdivided into groups according to their target molecule: antisense oligonucleotides (ODN), ribozymes, microRNAs inhibitors, and short interfering RNAs. These oligonucleotides interact by Watson–Crick base pairing with cellular transcripts leading to their degradation or functional inhibition. First antisense therapies have reached the patients. However, a requirement for the effective application of antisense therapy is based on three fundamental issues, and they are stability, site-specific delivery, and no off-target effects. This is, of course, also true for the employment of the other RNA molecules, such as siRNAs, microRNAs, or different ribozymes. To overcome the stability problems of RNA molecules in the human serum and in the cells, efforts have been directed to chemically modify these ribonucleic acids in such a way that they would become resistant to cellular ribonucleases. But with these modifications one may also increase the unwanted side effects, so that the problems of stability have so far not been optimally solved. Very promising approaches with these goals in mind are also presented in this book.

In the cells oligonucleotides are known to modulate gene expression by binding to proteins as aptamers, and not only that, in addition, the physiological binding to transcription factors to reduce their capacity to mediate gene transcription has also been observed. Very interesting and promising are also antisense molecules that recruit RNase H or RISC factors to mediate RNA hydrolysis. RNA interference, for example, is best known for its various roles in posttranscriptional gene silencing in the cytoplasm.

In this volume the reviewers discuss the general aspects of structure and function of ribonucleic acids as indicated above. Very interesting are the results reported, because they show how new and very promising RNA regulators can be developed for the next generation of therapeutic agents directed at various types of diseases.

In the book, we collected chapters on general aspects of RNA, its stability, and chemical modification. Several reviews highlight recent progress in development and application of antisense technologies for RNA silencing. The therapeutic potential of ribozymes and DNazymes is also extensively discussed. A current knowledge on microRNA pathways in human diseases is covered in several chapters and will help to round up the current knowledge of RNA technologies and as these technologies may be applied in the field of future molecular medicine.

Contents

RNAissance	1
Juergen Brosius	
Nucleic Acids as Therapeutics	19
Saraswat Pushpendra, Pareek Arvind, and Bhandari Anil	
Thio Effects as a Tool for Mechanistic Studies of the Cleavage of RNA Phosphodiester Bonds: The Chemical Basis	47
Mikko Ora, Tuomas Lönnberg, and Harri Lönnberg	
Off-Target Effects and Safety Aspects of Phosphorothioate Oligonucleotides	67
Martina Stessl, Christian R. Noe, and Johannes Winkler	
Oligonucleotide Conjugates: Rationale, Synthesis, and Applications	85
Yashveer Singh, Pierre Murat, Nicolas Spinelli, and Eric Defrancq	
CRISPR: A Bacterial Immunity System Based on Small RNAs	121
Rolf Wagner and Ümit Pul	
Antisense Technology: From Unique Laboratory Tool to Novel Anticancer Treatments	145
Christine Di Cresce, Colin Way, Mateusz Rytelowski, Saman Maleki Vareki, Supritha Nilam, Mark D. Vincent, James Koropatnick, and Peter J. Ferguson	
Antisense-Mediated Reduction of Eukaryotic Noncoding RNAs	191
Xue-hai Liang, Timothy A. Vickers, and Stanley T. Crooke	
Antisense Oligonucleotides in the Treatment of Malignant Gliomas	215
Gerardo Caruso, Mariella Caffo, Giuseppe Raudino, Federica Raudino, Mario Venza, and Francesco Tomasello	

Natural Antisense Transcripts Mediate Regulation of Gene Expression	247
Marco Magistri and Mohammad Ali Faghihi	
Activation and Deactivation of Antisense and RNA Interference Function with Light	275
Jeane M. Govan and Alexander Deiters	
Ribozymes as Molecular Biology Reagents	293
Sanchita Bhadra, Arti Pothukuchy, and Andrew Ellington	
RNA Technologies for Mitochondrial Genetics	313
André Dietrich, Katarzyna Rolle, Marta Gabryelska, Eliza Wyszko, Romain Val, Maciej Szymanski, Clarisse Valentin, Anne Cosset, and Jan Barciszewski	
RNA-Based Therapies for Inherited Metabolic Diseases	357
Belén Pérez, Magdalena Ugarte, and Lourdes R. Desviat	
RNA-Cleaving DNA Enzymes and Their Potential Therapeutic Applications as Antibacterial and Antiviral Agents	371
P.I. Pradeepkumar and Claudia Höbartner	
Hammerhead Ribozymes Against Virus and Viroid RNAs	411
Alberto Carbonell, Ricardo Flores, and Selma Gago	
Suppression of Hepatitis C Viral Genome Replication with RNA-Cleaving Deoxyribozyme	429
Dal-Hee Min and Dong-Eun Kim	
Design of Synthetic shRNAs for Targeting Hepatitis C: A New Approach to Antiviral Therapeutics	453
Brian H. Johnston and Qing Ge	
The Diverse Active Sites in Splicing, Debranching, and MicroRNA Processing Around RNA Phosphodiester Bonds	475
Sourav Kumar Dey, Eduardo Paredes, Molly Evans, and Subha R. Das	
MicroRNAs and Their Antagonists as Novel Therapeutics	503
Jeppe Vinther, Jakob Lewin Rukov, and Noam Shomron	
microRNAs in Human Diseases and Viral Infections	525
Alessandra Mescalchin and Tobias Restle	
Dysregulation of MicroRNA Expression and Human Diseases?	553
To-Ha Thai	
Noncoding RNAs: Identification of Cancer-Associated MicroRNAs	573
Muller Fabbri and George A. Calin	

Targeting Non-coding RNAs for Cancer Therapy	589
Satya K. Kota and Savithri Balasubramanian	
MicroRNA Pathways in <i>Drosophila</i>	611
Geetanjali Chawla and Nicholas S. Sokol	
Viroids: The Smallest Known Infectious Agents Cause Accumulation of Viroid-Specific Small RNAs	629
Jaroslav Matoušek, Detlev Riesner, and Gerhard Steger	
Index	645

